Enroflox™ (enrofloxacin) (Manufacturer may vary)

Enroflox™ (enrofloxacin) Injection For Dogs 2.27% is a fluoroquinolone designed for the management of bacterial diseases, with broad-spectrum activity against both gram-negative and gram-posotive bacteria including those causing dermal, urinary and respiratory tract infections.

Key Benefits:

Same active ingerdient, formulation and dosing regimen as Baytril® Injectable Solution 2.27%

Concentration-dependent and bactericidal

Kills a broad range of Gram (+) and Gram (-) Bacteria

Significant savings versus Baytril Injectable Solution 2.27%

Dosage & Administration

may be used as the initial dose at 2.5 mg/kg. It should be administered intrmuscularly (IM) as a single dose, followed by initiation of enrofloxacin tablet theraphy.

Enroflox Injection May be Administered as Follows: Weight of Animal Enroflox® Injection for Dogs* 2.5 mg/kg 4.5 kg (10 lb.) 0.50 ml 6.8 kg (15 lb.) 0.75 ml 9.1 kg (20 lb.) 1.00 ml 11.3 kg (25 lb.) 1.25 ml 13.6 kg (30 lb.) 1.50 ml 15.9 kg (35 lb.) 1.75 ml 18.1 kg (40 lb.) 2.00 ml 20.4 kg (45 lb.) 2.25 ml 22.7 kg (50 lb.) 2.50 ml *The initial Enroflox Injection administration should be followed 12 hours later by initiation of enrofloxacin tablet theraphy. The lower limit of the dose range was based on efficacy studies in dogs where enrofloxacin was administered at 2.5 mg/kg twice daily. Target animal safety and toxicology studies were used to establish the upper limit of the dose range and treatment duration.

Contraindictions, Warnings etc:
Enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. Based on the studies discussed under the section on Animal Safety Summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). The safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. Large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. In clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. However, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

Caution: Federal (US) law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra label use of this drug in food-producing animals.

WARNINGS: For use in animals only. The use of this product in cats may result in Retinal Toxicity. Keep out of reach of children. Observe label instructions and see product insert for full product information.